Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol.
Article Details
- CitationCopy to clipboard
Wang BH, Lu ZX, Polya GM
Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol.
Planta Med. 1998 Apr;64(3):195-9.
- PubMed ID
- 9581512 [ View in PubMed]
- Abstract
The protein tyrosine kinase (PTK) inhibitor piceatannol is also an inhibitor of the rat liver cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK), rat brain Ca(2+)- and phospholipid-dependent protein kinase C (PKC), avian gizzard Ca(2+)-calmodulin-dependent myosin light chain kinae (MLCK), and of wheat embryo Ca(2+)-dependent protein kinase (CDPK) (IC50 values 3, 8, 12, and 19 microM, respectively). However, a number of piceatannol-related compounds with fewer or no phenolic hydroxy substituents are inactive or very poor inhibitors of these serine/threonine protein kinases. Similarly, the PTK inhibitor ellagic acid is a potent inhibitor of cAK and of PKC (IC50 values 2 and 8 microM, respectively), whereas the non-phenolic perylene is ineffective as a protein kinase inhibitor. Ellagic acid is a competitive inhibitor of both cAK and of PKC but piceatannol inhibits these enzymes in a fashion that is competitive and non-competitive, respectively. Interaction with calmodulin may contribute to the inhibition of MLCK and CDPK by piceatannol.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ellagic acid cAMP-dependent protein kinase catalytic subunit alpha Protein Humans UnknownInhibitorDetails Ellagic acid Protein kinase C alpha type Protein Humans UnknownInhibitorDetails Ellagic acid Protein kinase C beta type Protein Humans UnknownInhibitorDetails